Biogen CEO Michel Vounatsos (via Getty Images)
With aducanumab caught on a cliff, Biogen’s Michel Vounatsos bets billions on another high-risk neuro play
With its FDA pitch on the Alzheimer’s drug aducanumab hanging perilously close to disaster, Biogen is rolling the dice on a $3.1 billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
